Cell surface antibody–associated neurodegeneration
The case of anti-IgLON5 antibodies
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Cell surface autoantibodies have become important biomarkers of acquired autoimmune CNS disorders, and typically define potentially severe but treatable acquired autoimmune encephalitis syndromes. However, the discovery of anti-IgLON5 antibodies has forced a reappraisal of the accepted paradigms regarding cell surface antibodies and their associated clinical manifestations.1 Although anti-IgLON5 antibody is a cell surface antibody, the clinical syndrome is not an encephalitis (there is no lymphocytic inflammatory infiltration), disease onset is more chronic rather than acute, and the neurologic sequelae are not reversible with immunotherapy in most patients, with progressive neurodegeneration and high mortality. This is therefore a novel autoimmune CNS syndrome, inhabiting the borderland between autoimmunity and neurodegeneration: cell surface antibody–associated neurodegeneration. The article by Gaig et al.2 in this issue of Neurology® extends our knowledge of the clinical features of this rare but important form of autoimmune neurodegeneration. The study describes 22 patients who were positive for anti-IgLON5 autoantibodies, as tested by the Neuroimmunology Laboratory in Barcelona, comprising the largest cohort with this condition. The main findings were that the clinical syndrome can present with sleep, brainstem, gait, cognitive, or movement disorders, but during the disease course all patients develop manifestations of disordered sleep and ventilation. The course was chronic and progressive in most patients, and 59% died during follow-up. It should be noted that it is possible that the initial description of this condition has resulted in recruitment bias, and the spectrum of symptoms and signs is different from what is described by Gaig et al.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1736
- © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan